Search
Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data
He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy. Coverage brought to you by
Apr 14
Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial readouts scheduled in DMD and DM1 over the next year
He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data. Coverage brought to you by
Oct 14, 2025
.png){kind=logo}
